It was initially approved only for patients with the CFTR G551D mutation, the third most common mutation (the G551D mutation, at least on one allele, is detected in ~4–5% of patients with CF) [4], but has now be authorized for 97 CFTR mutations with lower prevalence. Here, CFTR is linked to cystic fibrosis.